JPWO2020236654A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020236654A5 JPWO2020236654A5 JP2021568427A JP2021568427A JPWO2020236654A5 JP WO2020236654 A5 JPWO2020236654 A5 JP WO2020236654A5 JP 2021568427 A JP2021568427 A JP 2021568427A JP 2021568427 A JP2021568427 A JP 2021568427A JP WO2020236654 A5 JPWO2020236654 A5 JP WO2020236654A5
- Authority
- JP
- Japan
- Prior art keywords
- cbl
- inhibitor
- cancer
- cells
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849722P | 2019-05-17 | 2019-05-17 | |
| US62/849,722 | 2019-05-17 | ||
| US201962880437P | 2019-07-30 | 2019-07-30 | |
| US62/880,437 | 2019-07-30 | ||
| US201962888870P | 2019-08-19 | 2019-08-19 | |
| US201962888845P | 2019-08-19 | 2019-08-19 | |
| US62/888,870 | 2019-08-19 | ||
| US62/888,845 | 2019-08-19 | ||
| PCT/US2020/033274 WO2020236654A1 (en) | 2019-05-17 | 2020-05-15 | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532247A JP2022532247A (ja) | 2022-07-13 |
| JP2022532247A5 JP2022532247A5 (https=) | 2023-05-23 |
| JPWO2020236654A5 true JPWO2020236654A5 (https=) | 2023-05-23 |
| JP7587528B2 JP7587528B2 (ja) | 2024-11-20 |
Family
ID=70978642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568427A Active JP7587528B2 (ja) | 2019-05-17 | 2020-05-15 | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11530229B2 (https=) |
| EP (1) | EP3969447A1 (https=) |
| JP (1) | JP7587528B2 (https=) |
| CN (1) | CN114206855B (https=) |
| AU (1) | AU2020278592B2 (https=) |
| CA (1) | CA3140873A1 (https=) |
| MX (1) | MX2021013751A (https=) |
| WO (1) | WO2020236654A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) * | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2022169998A1 (en) * | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Amides as cbl-b inhibitors |
| AR124800A1 (es) * | 2021-02-03 | 2023-05-03 | Genentech Inc | Lactamas como inhibidores cbl-b |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| JP2024542117A (ja) | 2021-11-05 | 2024-11-13 | ジェネンテック， インコーポレイテッド | Ｃ－ｃｂｌに対して選択的なｃｂｌ－ｂ阻害剤としてのラクタム |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| JP2025523057A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１ |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AR129946A1 (es) * | 2022-07-18 | 2024-10-16 | Insilico Medicine Ip Ltd | Inhibidores de cbl-b y métodos de uso de los mismos |
| US20260028336A1 (en) * | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| JP2025525947A (ja) | 2022-08-16 | 2025-08-07 | グレンマーク ファーマシューティカルズ エルティーディー | Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
| WO2024105563A1 (en) * | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024112692A1 (en) * | 2022-11-21 | 2024-05-30 | Arvinas Operations, Inc. | Casitas b-lineage lymphoma protooncogene b (cbl-b) degrading compounds and associated methods of use |
| CN115887450B (zh) * | 2022-12-09 | 2024-06-25 | 杭州师范大学 | 角鲨烯化替莫唑胺的合成及其自组装纳米粒的制备和应用 |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| TW202435863A (zh) | 2023-01-28 | 2024-09-16 | 芬蘭商奧利安公司 | Cbl-b抑制劑 |
| CN121816192A (zh) | 2023-09-14 | 2026-04-07 | 因斯布鲁克医科大学 | 通过抑制NR2f6增强CAR-T细胞疗效 |
| CN118324623A (zh) * | 2024-04-12 | 2024-07-12 | 丽珠集团福州福兴医药有限公司 | 一种2-甲基-4-乙酰基苯甲酸的合成方法 |
| WO2026022742A1 (en) * | 2024-07-23 | 2026-01-29 | Bridgene Biosciences Limited | Cbl-b inhibitor and uses thereof |
| WO2026022749A2 (en) | 2024-07-26 | 2026-01-29 | Aurigene Oncology Limited | Cbl-b inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| CA2437248A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CN101365806B (zh) | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
| ES2566502T3 (es) | 2006-09-13 | 2016-04-13 | The Trustees Of Columbia University In The City Of New York | Agentes y métodos para provocar una respuesta inmune antitumoral |
| AT506041A1 (de) * | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| CA2710462C (en) | 2008-02-05 | 2015-11-24 | F. Hoffmann-La Roche Ag | Pyridinones and pyridazinones |
| AR079545A1 (es) | 2009-12-21 | 2012-02-01 | Bayer Cropscience Ag | Tienilpiri(mi)dinilazol |
| KR101862327B1 (ko) | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| KR20150054994A (ko) | 2012-09-13 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| EP3325475B1 (en) * | 2015-07-17 | 2020-03-18 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3138905A1 (en) | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| EP3254701A1 (en) * | 2016-06-09 | 2017-12-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| WO2019063748A1 (en) * | 2017-09-30 | 2019-04-04 | Glaxosmithkline Intellectual Property Development Limited | INHIBITORS OF ROR-GAMMA |
| WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| WO2021021761A1 (en) | 2019-07-30 | 2021-02-04 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| IL310717A (en) | 2021-08-20 | 2024-04-01 | Biomea Fusion Inc | Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT |
-
2020
- 2020-05-15 EP EP20730876.8A patent/EP3969447A1/en active Pending
- 2020-05-15 CA CA3140873A patent/CA3140873A1/en active Pending
- 2020-05-15 JP JP2021568427A patent/JP7587528B2/ja active Active
- 2020-05-15 WO PCT/US2020/033274 patent/WO2020236654A1/en not_active Ceased
- 2020-05-15 AU AU2020278592A patent/AU2020278592B2/en active Active
- 2020-05-15 US US16/875,917 patent/US11530229B2/en active Active
- 2020-05-15 MX MX2021013751A patent/MX2021013751A/es unknown
- 2020-05-15 CN CN202080051333.0A patent/CN114206855B/zh active Active
-
2022
- 2022-12-19 US US18/068,195 patent/US12049471B2/en active Active
-
2024
- 2024-06-18 US US18/747,129 patent/US20240409555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020236654A5 (https=) | ||
| JPWO2020210508A5 (https=) | ||
| JPWO2020264398A5 (https=) | ||
| US12121579B2 (en) | Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT) | |
| US20230303702A1 (en) | Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen | |
| JPWO2021021761A5 (https=) | ||
| KR101764096B1 (ko) | 항-ｐｄ-ｌ1 항체 및 그의 용도 | |
| AU2004294842B2 (en) | Medicine containing genetically modified antibody against chemokine receptor CCR4 | |
| RU2294761C2 (ru) | Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса | |
| CN118206655A (zh) | 增强的嵌合抗原受体及其用途 | |
| US20210253729A1 (en) | Enhanced chimeric antigen receptors and use thereof | |
| EP3774920A1 (en) | Anti-pd-l1 antibodies and use thereof | |
| US20240270840A1 (en) | Antibodies against cd112r and uses thereof | |
| JP7771749B2 (ja) | 二重特異性タンパク質 | |
| WO2026017820A1 (en) | Fusion protein for cancer treatment | |
| EA051900B1 (ru) | Антитела против cd112r и варианты их применения | |
| HK40051993B (zh) | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |